Omxiclv (amoxicillin + clavulanic acid): Uses, Dosage & Side Effects

What it's for (Indications)

Amoxicillin and clavulanic acid is a widely utilized antibiotic combination indicated for the treatment of various bacterial infections caused by susceptible organisms, particularly those that produce beta-lactamase enzymes.
This synergistic formulation extends the antimicrobial spectrum of amoxicillin to include many bacteria that would otherwise be resistant.
Common indications encompass a broad range of infections, including but not limited to, otitis media (middle ear infection), sinusitis (inflammation of the sinuses), lower respiratory tract infections such as community-acquired pneumonia and acute bacterial exacerbations of chronic bronchitis, urinary tract infections, and skin and soft tissue infections.
Its efficacy against a diverse array of Gram-positive and Gram-negative bacteria, including *Haemophilus influenzae*, *Moraxella catarrhalis*, *Staphylococcus aureus* (methicillin-susceptible strains), *Streptococcus pneumoniae*, and *Escherichia coli*, makes it a valuable therapeutic option in clinical practice.
The decision to prescribe should always be based on susceptibility testing when possible, or clinical judgment in the absence of such data, to ensure appropriate antimicrobial stewardship and patient outcomes.

Dosage Information

Type	Guideline
Standard	The dosage of amoxicillin and clavulanic acid varies significantly based on the patient's age, weight, the severity and type of infection, and renal function. It is available in various strengths and formulations, including tablets and oral suspensions, which typically specify the amoxicillin component followed by the clavulanic acid component. For adults and adolescents, common oral dosages for mild to moderate infections include 500 mg amoxicillin / 125 mg clavulanic acid taken every 8 hours, or 875 mg amoxicillin / 125 mg clavulanic acid taken every 12 hours. For more severe infections or those of the respiratory tract, higher dosages like 875 mg/125 mg every 12 hours may be indicated. Pediatric dosing is primarily based on the amoxicillin component, often ranging from 20 mg/kg/day to 45 mg/kg/day, divided and administered every 8 or 12 hours, not exceeding adult dosages. It is crucial to administer this medication with food or a snack at the start of a meal to enhance absorption and minimize gastrointestinal intolerance. Patients with impaired renal function require dosage adjustments to prevent drug accumulation and potential toxicity. Adherence to the full prescribed course of therapy is paramount, even if symptoms improve, to ensure complete eradication of the infection and prevent the development of antibiotic resistance.

Type

Guideline

Standard

The dosage of amoxicillin and clavulanic acid varies significantly based on the patient's age, weight, the severity and type of infection, and renal function. It is available in various strengths and formulations, including tablets and oral suspensions, which typically specify the amoxicillin component followed by the clavulanic acid component. For adults and adolescents, common oral dosages for mild to moderate infections include 500 mg amoxicillin / 125 mg clavulanic acid taken every 8 hours, or 875 mg amoxicillin / 125 mg clavulanic acid taken every 12 hours. For more severe infections or those of the respiratory tract, higher dosages like 875 mg/125 mg every 12 hours may be indicated. Pediatric dosing is primarily based on the amoxicillin component, often ranging from 20 mg/kg/day to 45 mg/kg/day, divided and administered every 8 or 12 hours, not exceeding adult dosages. It is crucial to administer this medication with food or a snack at the start of a meal to enhance absorption and minimize gastrointestinal intolerance. Patients with impaired renal function require dosage adjustments to prevent drug accumulation and potential toxicity. Adherence to the full prescribed course of therapy is paramount, even if symptoms improve, to ensure complete eradication of the infection and prevent the development of antibiotic resistance.

Safety & Warnings

Common Side Effects

Amoxicillin and clavulanic acid, while generally well-tolerated, can cause a range of side effects, some of which may be serious.
The most frequently reported adverse effects are gastrointestinal in nature, including diarrhea, nausea, and vomiting.
These are often transient and can be mitigated by taking the medication with food.
Other common side effects include mucocutaneous candidiasis (e.
g.
, oral thrush or vaginal yeast infection), skin rash, and urticaria.
Less common but more serious adverse reactions warrant immediate medical attention.
These include severe hypersensitivity reactions such as anaphylaxis, Stevens-Johnson syndrome, and toxic epidermal necrolysis, which can be life-threatening.
Hepatic dysfunction, characterized by cholestatic jaundice or hepatitis, is a significant concern, particularly in older adults, males, and those on prolonged therapy; this can be severe and, in rare instances, fatal.
*Clostridium difficile*-associated diarrhea (CDAD) is another serious potential complication, ranging from mild diarrhea to fatal colitis, which can occur during or several weeks after antibiotic treatment.
Hematologic abnormalities like thrombocytopenia, leukopenia, and hemolytic anemia have also been reported rarely.
Any signs of severe allergic reaction, jaundice, dark urine, persistent abdominal pain, or severe watery diarrhea should prompt immediate cessation of the drug and medical evaluation.

Serious Warnings

Black Box Warning: Amoxicillin and clavulanic acid is not associated with an FDA-mandated Black Box Warning. However, healthcare professionals and patients must be acutely aware of several critical safety considerations due to the potential for severe adverse reactions. The most significant serious warnings include the risk of severe hypersensitivity reactions, including anaphylaxis, which can be life-threatening. Patients with a history of penicillin allergy, or even severe allergic reactions to other beta-lactams, should not receive this medication due to the potential for cross-reactivity. Another paramount concern is the risk of hepatotoxicity, manifesting as cholestatic jaundice or hepatitis. This adverse effect can be severe, occasionally fatal, and is more common in males, elderly patients, and those receiving prolonged therapy or higher doses. Liver function should be monitored, and the drug should be discontinued immediately if signs of liver injury appear. Furthermore, the potential for *Clostridium difficile*-associated diarrhea (CDAD), ranging from mild diarrhea to fatal colitis, necessitates careful consideration, especially with prolonged use or in patients with pre-existing gastrointestinal conditions. These serious warnings underscore the importance of careful patient selection, monitoring, and prompt recognition of adverse events to ensure patient safety.
Several critical warnings and precautions are associated with the use of amoxicillin and clavulanic acid that necessitate careful consideration by healthcare professionals.
Foremost among these is the potential for severe, and occasionally fatal, hypersensitivity (anaphylactic) reactions.
These reactions are more likely to occur in individuals with a history of penicillin allergy or a history of sensitivity to multiple allergens.
Therefore, a thorough inquiry into previous allergic reactions to penicillins, cephalosporins, or other beta-lactams is imperative before initiating therapy.
Cross-reactivity between penicillins and cephalosporins has been documented.
Another significant warning pertains to the risk of hepatotoxicity, including cholestatic jaundice and hepatitis.
This adverse effect can be severe, occurring more frequently in males and older patients, and with prolonged use.
Liver function should be monitored, and the drug discontinued if signs of hepatic impairment develop.
Furthermore, the use of nearly all antibacterial agents, including this combination, has been associated with *Clostridium difficile*-associated diarrhea (CDAD), which can range in severity from mild diarrhea to fatal colitis.
This must be considered in all patients who present with diarrhea following antibiotic use.
Dosage adjustments are required for patients with renal impairment to prevent drug accumulation and potential neurotoxicity.
Patients with infectious mononucleosis should avoid amoxicillin-containing products due to a high incidence of maculopapular rash.
Prolonged use of this antibiotic may also result in the overgrowth of non-susceptible organisms, necessitating careful monitoring for superinfections.

How it Works (Mechanism of Action)

Amoxicillin and clavulanic acid is a combination antimicrobial agent that exerts its bactericidal effects through a dual mechanism. Amoxicillin, a semisynthetic aminopenicillin, functions by inhibiting bacterial cell wall synthesis. It achieves this by binding to specific penicillin-binding proteins (PBPs) located within the bacterial cell wall, which are essential for the synthesis of peptidoglycan, a crucial component of the bacterial cell wall. This binding prevents the cross-linking of peptidoglycan strands, leading to a defective and weakened cell wall, ultimately resulting in bacterial cell lysis and death. However, many bacteria produce beta-lactamase enzymes, which hydrolyze the beta-lactam ring of amoxicillin, rendering it inactive. This is where clavulanic acid plays its pivotal role. Clavulanic acid is a beta-lactamase inhibitor, structurally related to the penicillins, but possessing minimal antibacterial activity on its own. Its primary function is to irreversibly bind to and inactivate a wide range of clinically important beta-lactamase enzymes produced by various Gram-positive and Gram-negative bacteria. By protecting amoxicillin from degradation by these enzymes, clavulanic acid effectively extends the antimicrobial spectrum of amoxicillin to include many beta-lactamase-producing strains that would otherwise be resistant, thereby restoring amoxicillin's activity against these pathogens.